Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Norikazu Tamaoki is active.

Publication


Featured researches published by Norikazu Tamaoki.


British Journal of Cancer | 1998

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer.

Tetsuji Tokunaga; Y Oshika; Yoshiyuki Abe; Yuichi Ozeki; S. Sadahiro; Hiroshi Kijima; T Tsuchida; Hitoshi Yamazaki; Yoshito Ueyama; Norikazu Tamaoki; Masato Nakamura

Vascular endothelial growth factor (VEGF) is a well known factor that induces angiogenesis. Four isoforms, i.e. VEGF206, 189, 165, and 121, have been identified. We examined the isoform patterns of VEGF mRNA using reverse transcription polymerase chain reaction (RT-PCR) analysis in 61 colon cancers. All the colon cancers examined expressed VEGF121. The isoform patterns were classified into three groups: type 1, VEGF121; type 2, VEGF121 + VEGF165; type 3, VEGF121 + VEGF165 + VEGF189. Three of the 61 colon cancers examined showed type 1 expression, 26 showed type 2 expression and 32 showed the type 3 pattern. The patients with liver metastases showed the type 3 isoform expression pattern at a significantly higher incidence (12 of 16, 75%) than those without liver metastasis (20 of 45, 44%) (P=0.036). The type 3 isoform pattern was significantly associated with M1 stage (P=0.019). The patients with colon cancer and the type 3 isoform pattern showed significantly poor prognosis (P < 0.01, Cox-Mantel). The colon cancers with the type 3 pattern showed a significantly higher involvement of veins (P=0.006). These observations suggest that the aberrant type 3 expression pattern of VEGF189 mRNA isoforms is correlated with liver metastasis, M stage, and poor prognosis in colon cancer.


Journal of Immunology | 2002

Functional Human T Lymphocyte Development from Cord Blood CD34+ Cells in Nonobese Diabetic/Shi-scid, IL-2 Receptor γ Null Mice

Takashi Yahata; Kiyoshi Ando; Yoshihiko Nakamura; Yoshito Ueyama; Kazuo Shimamura; Norikazu Tamaoki; Shunichi Kato; Tomomitsu Hotta

An experimental model for human T lymphocyte development from hemopoietic stem cells is necessary to study the complex processes of T cell differentiation in vivo. In this study, we report a newly developed nonobese diabetic (NOD)/Shi-scid, IL-2Rγ null (NOD/SCID/γcnull) mouse model for human T lymphopoiesis. When these mice were transplanted with human cord blood CD34+ cells, the mice reproductively developed human T cells in their thymus and migrated into peripheral lymphoid organs. Furthermore, these T cells bear polyclonal TCR-αβ, and respond not only to mitogenic stimuli, such as PHA and IL-2, but to allogenic human cells. These results indicate that functional human T lymphocytes can be reconstituted from CD34+ cells in NOD/SCID/γcnull mice. This newly developed mouse model is expected to become a useful tool for the analysis of human T lymphopoiesis and immune response, and an animal model for studying T lymphotropic viral infections, such as HIV.


Japanese Journal of Cancer Research | 1990

A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors.

Hitoshi Yamazaki; Yoshito Ohba; Norikazu Tamaoki; Masabumi Shibuya

Two transplantable cell lines of human glioblastoma multiforme GL‐3 and GL‐5 carried an amplification and overexpression of structurally altered epidermal growth factor (EGF) receptor gene: the 140 kilodalton EGF receptors in these cases exhibited a constitutively expressed tyrosine kinase activity without the ligand. Here, we isolated the abnormal EGF receptor cDNA from GL‐5 cell line, and demonstrated that this cDNA bears a single large intramolecular deletion mutation 801 base pairs long within the ligand binding domain of EGF receptor. In other regions no amino acid substitution was observed. At the level of genomic DNA, this deletion appeared to start from the 1st intron and terminate in the 6th intron of the EGF receptor gene. However, in the two lines of glioblastoma, GL‐3 and GL‐5, the positions of the start or the end of the deletion mutation in these introns were not identical, suggesting an involvement of a unique recombination mechanism in the formation of deletion mutation. A weak but ligand‐independent transforming activity was observed in the deletion‐carrying EGF receptor cDNA.


European Journal of Cancer | 1999

Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma.

M Tomisawa; Tetsuji Tokunaga; Y Oshika; T Tsuchida; Y Fukushima; H Sato; Hiroshi Kijima; Hitoshi Yamazaki; Yoshito Ueyama; Norikazu Tamaoki; Masato Nakamura

Vascular endothelial growth factor (VEGF) has five isoforms (VEGF206, 189, 165, 145 and 121). Increased VEGF expression in renal cell carcinoma (RCC) is associated with angiogenesis, but, it is not apparent which isoform is involved in this effect. We examined the isoform patterns of VEGF by reverse transcription-polymerase chain reaction (RT-PCR) in 47 RCCs. All showed increased VEGF expression as compared with extraneoplastic renal tissue. Four of the 47 RCCs showed VEGF121 alone, 10 showed VEGF121 + 165, and 33 showed the VEGF121 + 165 + 189 pattern. Patients with pathological stage pT3-4 RCC showed the VEGF121 + 165 + 189 isoform pattern at a significantly higher incidence (10/10, 100%) than those with pT0-2 (23/37, 62%) (P < 0.022). The VEGF121 + 165 + 189 isoform pattern was also significantly associated with high vessel counts and density (P = 0.0002, Mann-Whitney U test). These observations suggested that the VEGF189 mRNA isoform is closely associated with angiogenesis and results in the growth of RCC.


European Journal of Cancer | 1999

Cell-retained Isoforms of Vascular Endothelial Growth Factor (VEGF) are Correlated with Poor Prognosis in Osteosarcoma

Yoon Hwan Lee; Tetsuji Tokunaga; Y Oshika; Ryuji Suto; K Yanagisawa; M Tomisawa; H Fukuda; H Nakano; S Abe; A Tateishi; Hiroshi Kijima; H Yamazaki; Norikazu Tamaoki; Yoshito Ueyama; Masato Nakamura

Vascular endothelial growth factor (VEGF) is a major angiogenic factor. Osteosarcoma is characterised by hypervascularity and metastatic potential. We examined VEGF mRNA expression, VEGF isoform pattern and VEGF receptor (flt-1 and KDR) by RT-PCR analysis in 30 osteosarcomas. All 30 osteosarcomas expressed VEGF mRNA. 17 osteosarcomas (57%) expressed flt-1 mRNA, whilst 20 (67%) expressed KDR mRNA. 6/30 (20%) osteosarcomas were positive for VEGF121 only, 8 (27%) for VEGF121 + VEGF165, and 16 (53%) for VEGF121 + VEGF165 + VEGF189. Patients with osteosarcomas with VEGF165 (n = 24) had significantly poorer prognosis in comparison with those without VEGF165 (P = 0.022, Wilcoxons test). The osteosarcomas with VEGF165 had significantly increased vascularity assessed on sections immunostained for CD34 (P < 0.001, Mann-Whitney U test). Although VEGF165 is a soluble isoform, it is also retained on the cellular surface. These results suggest that cell-retained VEGF isoforms (VEGF165, VEGF189) might be essential for neovascularisation in osteosarcoma, whilst the soluble VEGF121 isoform is not sufficient to stimulate neovascularisation in this type of neoplasm.


British Journal of Cancer | 1999

Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer

Tetsuji Tokunaga; Masato Nakamura; Y Oshika; Yoshiyuki Abe; Yuichi Ozeki; Y Fukushima; Hiroyuki Hatanaka; S. Sadahiro; Hiroshi Kijima; T Tsuchida; H Yamazaki; Norikazu Tamaoki; Yoshito Ueyama

SummaryTwo subtypes of thrombospondin (TSP-1 and TSP-2) have inhibitory roles in angiogenesis in vitro, although the biological significance of these TSP isoforms has not been determined in vivo. We examined TSP-1 and TSP-2 gene expression by reverse transcription polymerase chain reaction (RT-PCR) analysis in 61 colon cancers. Thirty-eight of these 61 colon cancers were positive for TSP-2 expression and showed hepatic metastasis at a significantly lower incidence than those without TSP-2 expression (P = 0.02). TSP-2 expression was significantly associated with M0 stage in these colon cancers (P = 0.03), whereas TSP-1 expression showed no apparent correlation with these factors. The colon cancer patients with TSP-2 expression showed a significantly low frequency of liver metastasis correlated with the cell-associated isoform of vascular endothelial growth factor (VEGF-189) (P = 0.0006). Vascularity was estimated by CD34 staining, and TSP-2(–)/VEGF-189(+) colon cancers showed significantly increased vessel counts and density in the stroma (P < 0.0001). TSP-2(–)/VEGF-189(+) colon cancer patients also showed significantly poorer prognosis compared with those with TSP-2(+) / VEGF-189(–) (P = 0.0014). These results suggest that colon cancer metastasis is critically determined by angiogenesis resulting from the balance between the angioinhibitory factor TSP-2 and angiogenic factor VEGF-189.


British Journal of Cancer | 1996

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.

Yutaka Tokuda; Yasuyuki Ohnishi; K. Shimamura; M. Iwasawa; Masumi Yoshimura; Yoshito Ueyama; Norikazu Tamaoki; T Tajima; T Mitomi

The c-erbB-2 product is thought to be a unique and useful target for antibody therapy of cancers overexpressing the c-erbB-2 gene. In vitro and in vivo anti-tumour effects of a humanised antibody against the extracellular domain of the c-erbB-2 gene product, rhu4D5, were examined. Rhu4D5 was less effective than its murine counterpart, mu4D5, for the direct antiproliferative activity against the c-erbB-2-overexpressing SK-BR-3 cell line. In vivo treatment of severe combined immunodeficient (SCID) mice carrying the c-erbB-2-overexpressing 4-1ST human gastric carcinoma xenograft with 4hu4D5 revealed that the recombinant protein had potent anti-tumour activity. Furthermore, cytotoxicity of human peripheral blood mononuclear cells against 4-1ST was significantly augmented with rhu4D5, but not with mu4D5. These results indicate that rhu4D5 might perform better in patients than predicted from preclinical studies.


The Journal of Urology | 1986

A New Mouse Model of Genetically Transmitted Polycystic Kidney Disease

Hisahide Takahashi; Yoshito Ueyama; Tsutomu Hibino; Yuko Kuwahara; Shuzo Suzuki; Kyoji Hioki; Norikazu Tamaoki

The clinical and pathologic characteristics of the murine polycystic kidney were examined in a mutant cy/cy mouse found in the KK strain, which is known to be a diabetic strain. This cy/cy mutant appeared to resemble human adult polycystic kidney disease in clinical course and morphology although inheritance was an autosomal recessive trait. Histologic studies of early postnatal animals suggested that cystic alterations might occur in any part of a collecting tubule or nephron. The cy/cy mutant might be a useful model animal for further investigation of early morphologic alterations and progression of cystic disease.


Cancer | 1984

Malignant granular cell tumor of the right sciatic nerve. Report of an autopsy case with electron microscopic, immunohistochemical, and enzyme histochemical studies

Kazuo Shimamura; R. Yoshiyuki Osamura; Yoshito Ueyama; Jun-Ichi Hata; Norikazu Tamaoki; Nobuo Machida; Hiroaki Fukuda; Keiichi Uemura

An autopsy case of a malignant granular cell tumor of the right sciatic nerve was reported. The surgically excised malignant granular cell tumor of a 43‐year‐old woman showed a close relationship with the sciatic nerve, and postmortem examination disclosed extensive metastases. Electron microscopic observations of the material obtained at surgery revealed many diagnostic granules containing myelin figures, as well as basement membrane‐like structures around some of the tumor cells. Electron microscopic acid phosphatase staining suggested that the granules could be of a lysosomal origin. Immunohistochemical investigation showed the presence of S‐100 protein in the tumor cells, a finding which is believed to be specific for the nervous system. And, focally, the cytoplasmic processes accompanied by basement membrane mimicked Schwann cells. This evidence suggested the highly malignant nature of the malignant granular cell tumor of probable Schwann cell origin.


Cancer Gene Therapy | 2000

Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.

T Tsuchida; Hiroshi Kijima; Sadaaki Hori; Y Oshika; Tetsuji Tokunaga; Kenji Kawai; H Yamazaki; Yoshito Ueyama; Kevin J. Scanlon; Norikazu Tamaoki; Masato Nakamura

Human pancreatic cancer is a lethal malignancy, and the lesions show a very high incidence of point mutations of the K-ras oncogene. These alterations can be used as potential targets for specific ribozyme (Rz)-mediated growth suppression of the cancer cells. We designed an anti-K-ras Rz against mutant K-ras gene transcripts (codon 12, GGT to GTT) and generated a recombinant adenovirus (rAd) to express the Rz (rAd/anti-K-ras Rz). More than 95% of Capan-1 human pancreatic cells were infected with rAd/anti-K-ras Rz when treated with the virus at 200 plaque-forming units/cell. The virus, rAd/anti-K-ras Rz, significantly suppressed mutant K-ras gene expression and inhibited the growth of Capan-1 cells. At 3 days postinfection, we observed maximum growth suppression of the cells, characteristic morphological changes of apoptosis such as nuclear condensation and oligonucleosomal DNA fragmentation, and suppression of bcl-2 oncoprotein. These changes were not found in control virus-infected cells. Our results indicated that the virus rAd/anti-K-ras Rz specifically down-regulated the K-ras/bcl-2 pathway and induced apoptotic changes in Capan-1 pancreatic carcinoma cells. High-efficiency adenovirus-mediated delivery of anti-K-ras Rz could become a significant gene therapy strategy against human pancreatic cancer.

Collaboration


Dive into the Norikazu Tamaoki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yasuyuki Ohnishi

Central Institute for Experimental Animals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge